The First International Congress on Clinical Neurology and
Epidemiology (Neuroepidemiology) scheduled to take place in Munich,
Germany
in August 27-30, 2009 is a unique congress for many reasons.
Neuroepidemiology has been perceived for a long time as a science
of incidence, prevalence, risk factors, natural history and prognosis of
neurological disorders. However, it is only one part of neuroepidemiology
called non-experimental neuroepidemiology. The other integral, but commonly
forgotten, part of neuroepidemiology is an experimental neuroepidemiology, a
research based on clinical trials of effectiveness or efficacy of various
interventions in neurological disorders.
This International Congress, for the first time, will bring
together scientists and experts in all major fields of experimental and
non-experimental neuroepidemiology. Thus, this will be the first entirely
clinical congress specifically (and uniquely) devoted to the prevention,
epidemiology and management of neurological disorders in human populations. Bringing
together neuroepidemiologists, practitioners, public health physicians and
health care policy makers will bridge the gap not only between trialists and
non-experimental neuroepidemiologists but also between academicians and
practicing physicians, thus facilitating the implementation of most effective,
evidence-based treatment, rehabilitation and preventative strategies of
neurological disorders. Combining scientific sessions in these two
interrelated fields of neuroepidemiology with two corresponding half-day
teaching courses and a one year-free on-line subscription to the journal of
Neuroepidemiology for all registered participants are additional unique
features of the Congress.
The main topics of the Congress that will be addressed during
plenary, platform and poster sessions include stroke, TIA, dementia, Parkinson’s
disease, multiple sclerosis, epilepsy, migraine, traumatic brain injury,
peripheral neuropathy, neuromuscular disorders, central nervous system
infections and tumours, neurological aspects of aging, neuropsychology and
neuropsychiatric disorders. We also plan Satellite Symposia that will be
complementary to the main topics of the Congress. The Congress features
internationally recognized invited speakers, platform lectures, oral
presentations and poster sessions, and will provide an ideal platform for
continuing education in all fields of experimental and non-experimental clinical
neuroepidemiology.
We hope that this International Congress will provide an excellent
opportunity for many neurologists, neurosurgeons, epidemiologists,
neuropsychologists, rehabilitation specialists, geriatricians, nurses, aged
care specialists and health care providers working in the area of experimental
and non-experimental epidemiology of neurological disorders to share their
ideas, research findings and experience.
Munich – the Bavarian state capital,
third largest city in Germany,
is an economic hub and leisure centre, a fountain for the joy of life, a focal
point of art and culture, and crossroads of history and modern times. Munich is an
architectural synthesis of the arts encompassing impressive examples of building
during various epochs of style, from Gothic through Renaissance to Art Nouveau
and Art Deco. Modern accents are set by the glass and steel constructions of
contemporary architecture, such as the Olympic tent roof and the high-rise
buildings of corporate headquarters.
On behalf of the Local Organising Committee of the Congress, we are
delighted to welcome you to Munich
in August 2009.
